TY - JOUR
T1 - Circulating tumour cells in the -omics era
T2 - how far are we from achieving the ‘singularity’?
AU - Visal, Tanvi H.
AU - den Hollander, Petra
AU - Cristofanilli, Massimo
AU - Mani, Sendurai A.
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/7/20
Y1 - 2022/7/20
N2 - Over the past decade, cancer diagnosis has expanded to include liquid biopsies in addition to tissue biopsies. Liquid biopsies can result in earlier and more accurate diagnosis and more effective monitoring of disease progression than tissue biopsies as samples can be collected frequently. Because of these advantages, liquid biopsies are now used extensively in clinical care. Liquid biopsy samples are analysed for circulating tumour cells (CTCs), cell-free DNA, RNA, proteins and exosomes. CTCs originate from the tumour, play crucial roles in metastasis and carry information on tumour heterogeneity. Multiple single-cell omics approaches allow the characterisation of the molecular makeup of CTCs. It has become evident that CTCs are robust biomarkers for predicting therapy response, clinical development of metastasis and disease progression. This review describes CTC biology, molecular heterogeneity within CTCs and the involvement of EMT in CTC dynamics. In addition, we describe the single-cell multi-omics technologies that have provided insights into the molecular features within therapy-resistant and metastasis-prone CTC populations. Functional studies coupled with integrated multi-omics analyses have the potential to identify therapies that can intervene the functions of CTCs.
AB - Over the past decade, cancer diagnosis has expanded to include liquid biopsies in addition to tissue biopsies. Liquid biopsies can result in earlier and more accurate diagnosis and more effective monitoring of disease progression than tissue biopsies as samples can be collected frequently. Because of these advantages, liquid biopsies are now used extensively in clinical care. Liquid biopsy samples are analysed for circulating tumour cells (CTCs), cell-free DNA, RNA, proteins and exosomes. CTCs originate from the tumour, play crucial roles in metastasis and carry information on tumour heterogeneity. Multiple single-cell omics approaches allow the characterisation of the molecular makeup of CTCs. It has become evident that CTCs are robust biomarkers for predicting therapy response, clinical development of metastasis and disease progression. This review describes CTC biology, molecular heterogeneity within CTCs and the involvement of EMT in CTC dynamics. In addition, we describe the single-cell multi-omics technologies that have provided insights into the molecular features within therapy-resistant and metastasis-prone CTC populations. Functional studies coupled with integrated multi-omics analyses have the potential to identify therapies that can intervene the functions of CTCs.
UR - http://www.scopus.com/inward/record.url?scp=85126004193&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126004193&partnerID=8YFLogxK
U2 - 10.1038/s41416-022-01768-9
DO - 10.1038/s41416-022-01768-9
M3 - Review article
C2 - 35273384
AN - SCOPUS:85126004193
SN - 0007-0920
VL - 127
SP - 173
EP - 184
JO - British journal of cancer
JF - British journal of cancer
IS - 2
ER -